Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Textual)

v3.3.1.900
Commitments and Contingencies (Details Textual)
1 Months Ended 12 Months Ended
Jul. 09, 2015
USD ($)
Jul. 07, 2014
shares
Jan. 31, 2012
USD ($)
Dec. 31, 2015
USD ($)
ft²
Dec. 31, 2014
USD ($)
Mar. 31, 2015
USD ($)
Commitments and Contingencies [Line Items]            
License Expiration Period     12 years      
Net Extinguished, Fair Value of Stock Consideration Received         $ 240,000  
License Costs       $ 12,500    
Payments for Royalties     $ 100,000      
Operating Leases, Future Minimum Payments Due           $ 12,500
Description on Civil Penalties for Failure to File an FBAR       greater of $100,000 per year or 50%    
Description of Lessor Leasing Arrangements, Operating Leases       The Company executed a 2 year lease agreement commencing in December 2015 and ending in December 2017.     
Licensor [Member]            
Commitments and Contingencies [Line Items]            
Area of Land | ft²       4,516    
Stock Issued During Period, Shares, Other | shares   15,036        
Valeant Pharmaceuticals International Inc [Member] | Licensing Agreements [Member]            
Commitments and Contingencies [Line Items]            
Payments to Acquire Intangible Assets $ 1,000,000          
Proceeds from Sale of Intangible Assets $ 32,500,000